---
title: "I-MAB (now NovaBridge Biosciences) lifts ADS sale limit to $50,000,000"
url: "https://aibio.space/news/i-mab-now-novabridge-biosciences-lifts-ads-sale-limit-50-000-000/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-07-11"
section: "Financings"
tickers: "NASDAQ:NBP"
source: "https://www.sec.gov/Archives/edgar/data/1778016/000119312525158201/d32469d424b5.htm"
summary: "The amendment raises the amount of American depositary shares the company may sell under a sales agreement with Leerink Partners. It has not sold any under"
---

By the aibio.space news desk.

Sources

- [NovaBridge Biosciences 424B5 (2025-07-11)](https://www.sec.gov/Archives/edgar/data/1778016/000119312525158201/d32469d424b5.htm)

[NBP](https://aibio.space/companies/novabridge-biosciences/)

2025-07-11

# I-MAB (now NovaBridge Biosciences) lifts ADS sale limit to $50,000,000

Tickers [NBP](https://aibio.space/companies/novabridge-biosciences/)

The amendment raises the amount of American depositary shares the company may sell under a sales agreement with Leerink Partners. It has not sold any under the agreement so far.

## Key facts

- **Company**: NovaBridge Biosciences (NASDAQ: NBP)

- **News type**: Financings

- **Primary source**: [NovaBridge Biosciences 424B5 (2025-07-11)](https://www.sec.gov/Archives/edgar/data/1778016/000119312525158201/d32469d424b5.htm)

*Midtown Manhattan and a downtown tower in haze. CC0, via rawpixel. The picture shows the field, not the companies named.*

I-MAB (now NovaBridge Biosciences) (Nasdaq: IMAB) filed Amendment No. 1 to its prospectus on July 11, 2025. The amendment raises the maximum amount of American depositary shares, or ADSs, the company may sell under a sales agreement. An ADS is a U.S.-traded certificate that represents shares of a foreign company. Each ten (10) ADSs represent twenty-three (23) ordinary shares.

The company signed the sales agreement with Leerink Partners LLC on May 2, 2025. Under the prospectus dated May 15, 2025, it could sell up to $21,000,000 of ADSs. It has not sold any ADSs under the agreement as of the date of the amendment.

The company says it is no longer subject to General Instruction I.B.5 of Form F-3, a rule that caps how much a smaller company can sell. The cap no longer applies because the market value of ordinary shares, including those represented by ADSs, held by non-affiliates equaled or exceeded $75.0 million as of June 9, 2025.

Under the amendment, the company may offer and sell ADSs with an aggregate offering price of up to $50,000,000. On July 10, 2025, the last reported sale price of the ADSs on Nasdaq was $2.05 per ADS. The ADSs are listed on the Nasdaq Global Market.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

NBP

NovaBridge Biosciences

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/i-mab-now-novabridge-biosciences-lifts-ads-sale-limit-50-000-000/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "I-MAB (now NovaBridge Biosciences) lifts ADS sale limit to $50,000,000", 2025-07-11, https://aibio.space/news/i-mab-now-novabridge-biosciences-lifts-ads-sale-limit-50-000-000/